RHEUMATRACE Trademark

Trademark Overview


On Tuesday, September 19, 2023, a trademark application was filed for RHEUMATRACE with the United States Patent and Trademark Office. The USPTO has given the RHEUMATRACE trademark a serial number of 79392510. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Thursday, June 27, 2024. This trademark is owned by Nordic Bioscience A/S. The RHEUMATRACE trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; diagnostic preparations, substances and materials; medical diagnostic test strips; diagnostic preparations for medical purposes; diagnostic agents for medical use

Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the de...
rheumatrace

General Information


Serial Number79392510
Word MarkRHEUMATRACE
Filing DateTuesday, September 19, 2023
Status641 - NON-FINAL ACTION - MAILED
Status DateThursday, June 27, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesDiagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; diagnostic preparations, substances and materials; medical diagnostic test strips; diagnostic preparations for medical purposes; diagnostic agents for medical use
Goods and ServicesDesign and development of blood-based biomarker assays to identify, quantify and analyse disease activity; design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the detection and measurement of biomarkers; testing samples for the presence of biomarkers; laboratory services; medical laboratory services; research laboratory services; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis for medical and pharmaceutical research services; advice, information and assistance relating to the foregoing

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 1, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, April 1, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNordic Bioscience A/S
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressDK

Trademark Events


Event DateEvent Description
Friday, April 5, 2024APPLICATION FILING RECEIPT MAILED
Monday, May 13, 2024ASSIGNED TO EXAMINER
Friday, May 31, 2024NON-FINAL ACTION WRITTEN
Thursday, March 28, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, April 1, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, June 14, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, June 27, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, July 15, 2024REFUSAL PROCESSED BY IB
Thursday, June 27, 2024REFUSAL PROCESSED BY MPU